Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Phase 2 RENEW trial underway; interim data expected in H2 2026.
/ 1648 items
#XY↓
ProQR Therapeutics Gets BofA Buy Initiation After Positive AX-0810 Phase 1 Data
AX-0810 Phase 1 shows dose-dependent bile acid increases and no serious adverse events, delivering the first human proof of concept for ProQR’s Axiomer RNA editing.
Cantor Fitzgerald Starts Coverage of Milestone Pharmaceuticals with Overweight Rating and $3 Target
Cantor Fitzgerald initiates Overweight coverage on Milestone, citing Cardamyst’s strong PSVT launch potential and $250-300M peak sales outlook.
Ultragenyx’s GENGLYCOS Becomes First FDA-Approved Gene Therapy for Glycogen Storage Disease Type Ia
Ultragenyx’s GENGLYCOS receives accelerated FDA approval as the first gene therapy targeting the root cause of GSDIa in patients aged 8 and older.
BMO Capital Initiates Coverage on 7 Biotech Stocks: Outperform Ratings for ALNY, ASND, BMRN & More
BMO Capital starts coverage on ALNY, ASND, BMRN, CATX & more with Outperform ratings and price targets. See full analyst insights and targets.
From Moderna to Sellas: The Next Major Catalyst in Cancer Vaccines
Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.